Author:
Weis Serge,Sonnberger Michael,Dunzinger Andreas,Voglmayr Eva,Aichholzer Martin,Kleiser Raimund,Strasser Peter
Reference57 articles.
1. Abate-Daga D, Ramello MC, Smalley I, Forsyth PA, Smalley KSM (2018) The biology and therapeutic management of melanoma brain metastases. Biochem Pharmacol 153:35–45.
https://doi.org/10.1016/j.bcp.2017.12.019
2. Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY (2018) Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol 19(1):e33–e42.
https://doi.org/10.1016/s1470-2045(17)30692-7
3. Berghoff AS, Preusser M (2017) Targeted therapies for melanoma brain metastases. Curr Treat Options Neurol 19(4):13.
https://doi.org/10.1007/s11940-017-0449-2
4. Bhargava R, Dabbs DJ (2018) Immunohistology of carcinoma of unknown primary site. In: Dabbs DJ (ed) Diagnostic immunohistochemistry. theranostic and genomic applications, 5th edn. Elsevier, Amsterdam, pp 219–260
5. Bohn JP, Pall G, Stockhammer G, Steurer M (2016) Targeted therapies for the treatment of brain metastases in solid tumors. Target Oncol 11(3):263–275.
https://doi.org/10.1007/s11523-015-0414-5